Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year—Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS)
Open Access
- 3 January 2020
- journal article
- research article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2020, 1-11
Abstract
Aim. Optimal revascularization strategy in multivessel (MV) coronary artery disease (CAD) eligible for percutaneous management (PCI) and surgery remains unresolved. We evaluated, in a randomized clinical trial, residual myocardial ischemia (RI) and clinical outcomes of MV-CAD revascularization using coronary artery bypass grafting (CABG), hybrid coronary revascularization (HCR), or MV-PCI. Methods. Consecutive MV-CAD patients (n = 155) were randomized (1 : 1 : 1) to conventional CABG (LIMA-LAD plus venous grafts) or HCR (MIDCAB LIMA-LAD followed by PCI for remaining vessels) or MV-PCI (everolimus-eluting CoCr stents) under Heart Team agreement on equal technical and clinical feasibility of each strategy. SPECT at 12 months (primary endpoint of RI that the trial was powered for; a measure of revascularization midterm efficacy and an independent predictor of long-term prognosis) preceded routine angiographic control. Results. Data are given, respectively, for the CABG, HCR, and MV-PCI arms. Incomplete revascularization rate was 8.0% vs. 7.7% vs. 5.7% (). Hospital stay was 13.8 vs. 13.5 vs. 4.5 days (), and sick-leave duration was 23 vs. 16 vs. 8 weeks (). At 12 months, RI was 5 (2, 9)% vs. 5 (3, 7)% vs. 6 (3, 10)% (median; Q1, Q3) with noninferiority values of 0.0006 (HCR vs. CABG) and 0.016 (MV-PCI vs. CABG). Rates of angiographic graft stenosis/occlusion or in-segment restenosis were 20.4% vs. 8.2% vs. 5.9% (). Clinical target vessel/graft failure occurred in 12.0% vs. 11.5% vs. 11.3% (). Major adverse cardiac and cerebral event (MACCE) rate was similar (12% vs. 13.4% vs. 13.2%; ). Conclusion. In this first randomized controlled study comparing CABG, HCR, and MV-PCI, residual myocardial ischemia and MACCE were similar at 12 months. There was no midterm indication of any added value of HCR. Hospital stay and sick-leave duration were shortest with MV-PCI. While longer-term follow-up is warranted, these findings may impact patient and physician choices and healthcare resources utilization. This trial is registered with NCT01699048.
Keywords
This publication has 33 references indexed in Scilit:
- Predicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)JACC: Cardiovascular Interventions, 2014
- Hybrid revascularization in multivessel coronary artery disease†European Journal of Cardio-Thoracic Surgery, 2013
- Ischemia Change in Stable Coronary Artery Disease Is an Independent Predictor of Death and Myocardial InfarctionJACC: Cardiovascular Imaging, 2012
- Nomograms for estimating coronary artery disease prognosis with gated stress myocardial perfusion SPECTJournal of Nuclear Cardiology, 2012
- Simultaneous Right and Left Heart Real-Time, Free-Breathing CMR Flow Quantification Identifies Constrictive PhysiologyJACC: Cardiovascular Imaging, 2012
- Improved Near-Term Coronary Artery Disease Risk Classification With Gated Stress Myocardial Perfusion SPECTJACC: Cardiovascular Imaging, 2010
- Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery DiseaseNew England Journal of Medicine, 2009
- Hybrid Cardiovascular ProceduresJACC: Cardiovascular Interventions, 2008
- Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic BurdenCirculation, 2008
- Comparison of Stenting with Minimally Invasive Bypass Surgery for Stenosis of the Left Anterior Descending Coronary ArteryNew England Journal of Medicine, 2002